Skip to content

A multicenter randomized controlled clinical trial of a non-invasive embryo quality evaluation

A multicenter randomized controlled clinical trial of a non-invasive embryo quality evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051408
Enrollment
Unknown
Registered
2021-09-23
Start date
2021-09-09
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Experimental group:niEVT+morphology assisted selection of single blastocyst for freeze-thaw embryo transfer
Control group:Single blastocyst was selected for freezing and thawing

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1.In accordance with IVF or ICSI indications, the first controlled ovulation induction cycle; 2.Female aged 20 to 43 years (both included), female body mass index was 18 to 25 kg/m^2; 3.Agreed with all Day3 embryos cultrued in blastocyst and undergoing single frozen-thawed blastocyst transfer; 4.Agree to transfer the single blastocyst of best quality in accordance with the embryo transfer sequence recommended in this study.

Exclusion criteria

Exclusion criteria: 1.At least one spouse has contraindications for IVF or ICSI; 2.Couples in which one partner has known abnormal karyotype or plans to have preimplantation genetic testing (PGT); 3.Unexplained recurrent miscarriage (more than 2 times); 4.Having a medical condition (of any kind) that affects the outcome of pregnancy: untreated hydrosalpian tube, untreated intrauterine infection, uterine fibroid diameter > 4cm, pelvic and abdominal benign tumor > 4cm, hCG daily endometrial thickness < 7mm, pituitary tumor and malignant tumor of various tissues and organs, etc. 5.Women with congenital or acquired uterine abnormalities such as uterine malformations (monohorny uterus, mediastinal uterus, or double uterus), adenomyosis, submucosal fibroids, or intrauterine adhesions; 6.Couples with severe male factor infertility, including azoospermia (non-ejaculation or retrograde ejaculation), azoospermia, occult azoospermia (no sperm in smear, sperm visible after centrifugation), severe teratoospermia (100% malformation of sperm), severe necrotic azoospermia (total sperm motility 0%), excluding azoospermia patients receiving sperm donation treatment.

Design outcomes

Primary

MeasureTime frame
Live birth rate;

Secondary

MeasureTime frame
Clinical pregnancy rate;Ongoing pregnancy rate;Early abortion rate;Cumulative Live birth;Ectopic pregnancy;Time to pregnancy;Late abortion rate;

Countries

China

Contacts

Public ContactYao Yuanqing

Chinese PLA General Hospital

yaoyuanqing@301hospital.com.cn+86 13911668272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026